Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?
Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy
obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3.
Studies rarely address the issues of improving host factors. The current study examines
1. whether adding vitamin D, a potent immunomodulator, could improve viral response and
shorten treatment duration (from 24 weeks to 12 weeks)
2. whether Vitamin D levels predictes negative treatment outcome.